Document is current
Any future updates will be listed below
-
Authors
Rossi, Sabrina H. https://orcid.org/0000-0001-7048-7158
Dombrowe, Victoria
Godfrey, Laura https://orcid.org/0000-0003-2393-9881
Bucaciuc Mracica, Teodora
Pita, Sara
Milne-Clark, Toby
Kyeremeh, Justicia https://orcid.org/0009-0008-1477-7829
Park, Gahee
Smith, Christopher G.
Lach, Radoslaw P.
Babbage, Anne
Warren, Anne Y.
Mitchell, Thomas J. https://orcid.org/0000-0003-0761-9503
Stewart, Grant D. https://orcid.org/0000-0003-3188-9140
Schwarz, Roland https://orcid.org/0000-0001-9155-4268
Massie, Charlie E. https://orcid.org/0000-0003-2314-4843
- License Information
-
More Information
Article History
Received: 19 June 2024
Revised: 4 December 2024
Accepted: 27 December 2024
First Online: 17 January 2025
Competing interests
: GDS has received educational grants from Pfizer, AstraZeneca, and Intuitive. Surgical; consultancy fees from Pfizer, Merck, MSD, EUSA Pharma, and CMR Surgical; travel expenses from Pfizer; and speaker fees from MSD and Pfizer. GDS is Clinical lead (urology) National Kidney Cancer Audit and Topic Advisor for the NICE kidney cancer guideline. AWY is a member of the Clinical Reference Group for the National Kidney Cancer Audit. All other authors declare no competing interests.
: Ethics approval was obtained (DIAMOND; Ethics REC ID 03/018, East of England—Cambridge Central Research Ethics Committee). Written informed consent was obtained from all participants involved in the study. All methods were performed in accordance with the relevant guidelines/regulations and are compliant with good scientific practice.
